See today's BioWorld
To read the full story, subscribe or sign in.

Alkermes launches phase I in MS with eye on Biogen's Tecfidera

July 18, 2014
By Michael Fitzhugh
Alkermes plc is ramping up a phase I study of ALKS-8700, a small-molecule prodrug of monomethyl fumarate (MMF) for the treatment of multiple sclerosis.
BioWorld